

Zydus receives final approval from the USFDA for Ivermectin Cream

Ahmedabad, India, 04 August, 2022

Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited) has received final approval from the United States Food and Drug Administration (USFDA) to market Ivermectin Cream, 1%. USRLD: Soolantra.

Ivermectin Cream is used for the treatment of inflammatory lesions of rosacea. The drug will be manufactured at the group's topical manufacturing facility at Ahmedabad, India.

Ivermectin Cream had annual sales of USD 176 million in the United States according to IQVIA data (IQVIA MAT June 2022).

The group now has 319 approvals and has so far filed over 420* ANDAs since the commencement of the filing process in FY 2003-04.

(*as of 31st March 2022)



**PRESS
RELEASE**

For further information please contact :
The Corporate Communications Department

Zydus Lifesciences Limited
(formerly known as Cadila Healthcare Limited)

Regd. Office : 'Zydus Corporate Park',
Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),
Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382
481, Gujarat, India. | Phone : +91-79-71800000,
+91-79-48040000 | website : www.zyduslife.com
CIN : L24230GJ1995PLC025878